Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Haleon, a leading independent consumer health company, has officially launched following its demerger from GSK plc. Trading on the London Stock Exchange began on July 18, 2022, with NYSE trading set to follow on July 20, 2022. Haleon boasts a robust brand portfolio, including Advil, Sensodyne, and TUMS, targeting an annual organic revenue growth of 4-6%. The company aims to address everyday health challenges and empower 50 million people by 2025. Haleon emphasizes its commitment to scientific innovation and consumer-centric solutions, focusing on the growing self-care market.